Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Mater Today (Kidlington). 2020 Nov 2;42:99–116. doi: 10.1016/j.mattod.2020.08.019

FIGURE 10.

FIGURE 10

(a) In vitro antigen and adjuvant delivery to bone marrow-derived dendritic cells (BMDCs) using bicontinuous nanospheres (BCNs). TLR4 agonist monophosphoryl lipid A (MPL) with antigen ovalbumin (Ova) were co-loaded in BCNs via FNP. The effects of BCNs and polymersomes (PS) on BMDC activation were compared by comparing the expression of cell surface markers. (Reprinted with permission from Ref. [168]. 2018, Royal Society of Chemistry.) (b) Quantification of DiO-labeled oxidized low-density lipoprotein (oxLDL) uptake by human monocyte-derived macrophages (hMDMs) after 24 h incubation with FNP-based AM micelles or NP and quantification of foam cell phenotype after 48 h incubation. (Reprinted with permission from Ref. [172]. 2012, John Wiley and Sons.) (c) Top: transgene expression of plasmid in the liver and lung after single-dose delivery of different lipid-based NPs. Bottom: biodistribution of lipid-based NPs in different organs 6 h after administration. (Reprinted with permission from Ref. [134]. 2018, Elsevier.)